MedTrace Logo

PSMA-PET Registry for Recurrent Prostate Cancer

NCT03718260 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3070

Last updated 2023-03-17

No results posted yet for this study

Summary

This study aims to institute a province-wide registry leveraging the availability of a new Positron Emission Tomography tracer, \[18F\]-DCFPyL and PET expertise across Ontario centers to improve our ability to characterize patterns of recurrence and personalize therapies in men with recurrent prostate cancer after primary treatment.

Conditions

  • Recurrent Prostate Cancer

Interventions

DIAGNOSTIC_TEST

[18F]-DCFPyL PET/ CT scan (PSMA PET)

Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).

Sponsors & Collaborators

  • Cancer Care Ontario

    collaborator OTHER

  • Centre for Probe Development and Commercialization

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Glenn Bauman, MD, FRCPC · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

  • Ur Metser, MD, FRCPC · University Health Network, Toronto

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-27
Primary Completion
2024-03-31
Completion
2025-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03718260 on ClinicalTrials.gov